Lavipharm SA banner

Intrinsic Value

The intrinsic value of Lavipharm SA (BXA0) under the Base Case is 2.169 EUR per share. Compared with the current market price of 1.398 EUR, the stock appears Undervalued by 36% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

BXA0 Intrinsic Value
€2.169
Undervaluation 36%
Intrinsic Value
Price €1.398
Alert me when BXA0 is below its intrinsic value
Today €1.302 · 6.9% below the current price

BXA0 is valued in line with its history. A discount of this size has been typical over the past 4 years.

Alternatives to BXA0

Fundamental Analysis

What Lavipharm Does

Pharmaceuticals Health Care

Lavipharm SA is a Greek pharmaceutical company that develops, makes, and sells medicines and health products. Its portfolio includes prescription drugs, over-the-counter remedies, and transdermal patches that deliver medicine through the skin. It also works with other drug companies through manufacturing, licensing, and distribution arrangements.

Headquarters
Greece GR
Employees
285
IPO date
Nov 8, 1995
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue BXA0 Research

Decided on Lavipharm? Get an email when BXA0 reaches the price you’d buy at. Free with an account.

Other Lavipharm listings

What is the Intrinsic Value of one BXA0 stock?

The intrinsic value for Lavipharm SA (BXA0) under the Base Case is 2.169 EUR.

Is BXA0 stock undervalued or overvalued?

Compared with the current market price of 1.398 EUR, the stock appears Undervalued by 36% .

How reliable are our estimates? See how past valuations played out
Back to Top